Figure 1From: Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer PFS and OS according to VEGF -1498 C/T genotypes in the bevacizumab-group (N = 111, Panels A1 and A2) and in the control group (N = 107, Panels B1 and B2).Back to article page